TIDMIDP
RNS Number : 0989X
InnovaDerma PLC
29 April 2021
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF
AMERICA (SUBJECT TO CERTAIN LIMITED EXCEPTIONS), AUSTRALIA, CANADA
OR JAPAN OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO
DO SO. PLEASE SEE THE IMPORTANT NOTICE AT THE OF THIS
ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION (EU NO.
596/2014) AS IT FORMS PART OF UNITED KINGDOM DOMESTIC LAW BY VIRTUE
OF THE EUROPEAN (WITHDRAWAL) ACT 2018 ("UK MAR").
29 April 2021
InnovaDerma PLC
("InnovaDerma" or the "Company")
Result of Open Offer and General Meeting
and
Director/PDMR Shareholding
InnovaDerma (LSE: IDP), a leading UK developer and supplier of
beauty, personal care and life sciences products, is pleased to
announce that, further to the announcement on 12 April 2021, the
Resolutions put to Shareholders at the General Meeting held earlier
today in connection with the 9,981,040 new ordinary shares pursuant
to the Placing and Open Offer (together the "Fundraising") were
duly passed. Voting was held by way of a poll and all of the votes
cast by way of the poll were cast in favour of the resolutions.
Unless otherwise defined herein, capitalised terms used in this
announcement shall have the same meaning as defined in the
announcement the Placing, and Open Offer made by the Company on 20
January 2021.
Result of Open Offer
In addition, the Company is pleased to announce that valid
applications have been received in respect of, and the Company will
issue, 1,449,469 Open Offer Shares, raising gross proceeds of
GBP0.5 million and taking the total proceeds of the Fundraising to
GBP4.5 million.
The Company received valid acceptances in excess of the
1,449,469 Open Offer Shares being offered to Qualifying
Shareholders. The Open Offer was significantly oversubscribed and
the Directors will use their discretion to undertake an appropriate
scaling back process.
Director/PDMR Shareholding
The Company has been notified that Ross Andrews, Non-Executive
Chairman of the Company has taken up entitlements to subscribe for
13,145 additional new Ordinary Shares under the Open Offer.
As a result of this transaction, Ross Andrews' beneficial
interest in the Company following Admission is 322,290 Ordinary
Shares representing 1.17 per cent of the Company's total voting
rights.
Admission & Total Voting Rights
Application has been made to the London Stock Exchange for the
9,981,040 New Ordinary Shares to be admitted to trading. It is
expected that Admission will become effective and dealings will
commence in the Second Admission Shares at 8.00 a.m. on 30 April
2021.
Following Admission, the Company will have in issue 27,374,673
Ordinary Shares, with no shares held in treasury. Shareholders may
use this figure as the denominator by which they are required to
notify their interest in, or change to their interest in, the
Company under the Disclosure Guidance and Transparency Rules.
Blake Hughes, CEO of InnovaDerma said:
"I would like to thank our current and new shareholders for
their commitment and strong vote of confidence in InnovaDerma.
Whilst we have made good progress over recent months, including
enhancing our digital marketing expertise and rolling out a new
Skinny Tan website, this investment opens up an exciting future for
transforming InnovaDerma. It will enable us to further accelerate
the execution of our sharpened Company strategy, shared in March,
through capital investment in our e-commerce and operational
capabilities, as well as strengthening the balance sheet.
"Through this new digital and consumer insight centric strategy,
and supported by our UK based, digitally focused board, we now have
the right agility, the right structure and the right resources in
place to succeed in the digital e-commerce driven world which we
live in today.
"This is an exciting time for New InnovaDerma and I look forward
to updating shareholders with our future progress."
Further enquiries
InnovaDerma
Blake Hughes c/o TB Cardew
finnCap Group
Geoff Nash/Kate Bannatyne/Edward Whiley +44 (0)207 220 0500
Alice Lane/Charlotte Sutcliffe - ECM www.finncap.com
----------------------------
TB Cardew
Shan Shan Willenbrock/ + 44 (0)7775 848537
Olivia Rosser + 44 (0)20 7930 0777
innovaDerma@tbcardew.com
----------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
Pursuant to the split First and Second Admissions, Blake Hughes,
Ross Andrews and Simon Pyper received a portion of their Placing
Shares on First Admission. Their remaining investment has been
included within the Second Admission along with Mark Ward as
detailed below.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mark Ward
------------------------------- -----------------------------------
2. Reason for the Notification
--------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- -----------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name InnovaDerma PLC
------------------------------- -----------------------------------
b) LEI 213800WRAP6W8VDL6B38
------------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------
a) Description of EUR0.10 each ("Ordinary Shares")
the Financial
instrument, type
of instrument
Identification IDP GB00BT9PTW34
code
------------------------------- -----------------------------------
b) Nature of the Satisfaction of the obligation
transaction to repay GBP500,000 loan facility
provided by Mark Ward through
the issuance of 1,428,571
Placing Shares.
------------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
35p 1,428,571
----------
------------------------------- -----------------------------------
d) Aggregated information: See 4c) above
Aggregated volume
Price
------------------------------- -----------------------------------
e) Date of the transaction 30 April 2021
------------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, Main
Market
------------------------------- -----------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Ross Andrews
------------------------------- ---------------------------------
2. Reason for the Notification
------------------------------------------------------------------
a) Position/status Non-Executive Chairman
------------------------------- ---------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ---------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name InnovaDerma PLC
------------------------------- ---------------------------------
b) LEI 213800WRAP6W8VDL6B38
------------------------------- ---------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------
a) Description of EUR0.10 each ("Ordinary Shares")
the Financial
instrument, type
of instrument
Identification IDP GB00BT9PTW34
code
------------------------------- ---------------------------------
b) Nature of the Purchase of Ordinary Shares
transaction
------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
35p 164,549
----------
------------------------------- ---------------------------------
d) Aggregated information: See 4c) above
Aggregated volume
Price
------------------------------- ---------------------------------
e) Date of the transaction 30 April 2021
------------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange, Main
Market
------------------------------- ---------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Blake Hughes
------------------------------- ---------------------------------
2. Reason for the Notification
------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- ---------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ---------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name InnovaDerma PLC
------------------------------- ---------------------------------
b) LEI 213800WRAP6W8VDL6B38
------------------------------- ---------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------
a) Description of EUR0.10 each ("Ordinary Shares")
the Financial
instrument, type
of instrument
Identification IDP GB00BT9PTW34
code
------------------------------- ---------------------------------
b) Nature of the Purchase of Ordinary Shares
transaction
------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
35p 90,843
----------
------------------------------- ---------------------------------
d) Aggregated information: See 4c) above
Aggregated volume
Price
------------------------------- ---------------------------------
e) Date of the transaction 30 April 2021
------------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange, Main
Market
------------------------------- ---------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Simon Pyper
------------------------------- ---------------------------------
2. Reason for the Notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- ---------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ---------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name InnovaDerma PLC
------------------------------- ---------------------------------
b) LEI 213800WRAP6W8VDL6B38
------------------------------- ---------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------
a) Description of EUR0.10 each ("Ordinary Shares")
the Financial
instrument, type
of instrument
Identification IDP GB00BT9PTW34
code
------------------------------- ---------------------------------
b) Nature of the Purchase of Ordinary Shares
transaction
------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
35p 50,468
----------
------------------------------- ---------------------------------
d) Aggregated information: See 4c) above
Aggregated volume
Price
------------------------------- ---------------------------------
e) Date of the transaction 30 April 2021
------------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange, Main
Market
------------------------------- ---------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBBGDSDDDDGBC
(END) Dow Jones Newswires
April 29, 2021 07:24 ET (11:24 GMT)
Innovaderma (LSE:IDP)
Historical Stock Chart
From Apr 2024 to May 2024
Innovaderma (LSE:IDP)
Historical Stock Chart
From May 2023 to May 2024